CLINICAL MANAGEMENT OF METABOLIC PROBLEMS IN PATIENTS WITH SCHIZOPHRENIA:SW

精神分裂症患者代谢问题的临床管理：SW

• 批准号: 7716895
• 负责人: THOMAS SCOTT STROUP
• 金额: $ 0.13万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-02 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7716895
• 关键词: Adverse effects; Benefits and Risks; Cardiovascular Diseases; Clinical Management; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Institution; Metabolic; Patients; Pharmaceutical Preparations; Research; Research Personnel; Resources; Risk Factors; Schizophrenia; Source; United States National Institutes of Health; cardiovascular risk factor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients with schizophrenia have been shown to have more metabolic abnormalities, which are indicators for cardiovascular risk, than their matched controls. Some of the medications used to treat schizophrenia are associated with these metabolic abnormalities. The best treatment strategies for patients with schizophrenia and metabolic risk factors for cardiovascular disease have not yet been established. This study seeks to understand the risks and benefits of switching to a new medication with a low liability of producing metabolic side effects versus staying on a medication with a high liability of producing metabolic side effects.

这个子项目是众多研究子项目之一